Oryzon Genomics (XMAD:ORY) Profitability Rank: 0 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XMAD:ORY Oryzon Genomics SA XMAD:ORY
29 GF Score
Price €2.85
View Full Analysis

What is Oryzon Genomics Profitability Rank?

Oryzon Genomics has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Oryzon Genomics's Operating Margin % for the quarter that ended in Mar. 2026 was %. As of today, Oryzon Genomics's Piotroski F-Score is 4.


Oryzon Genomics Profitability Rank Related Terms


XMAD:ORY vs VRTX, REGN, ALNY: Profitability Rank Comparison

For the Biotechnology subindustry, Oryzon Genomics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oryzon Genomics Profitability Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oryzon Genomics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Oryzon Genomics's Profitability Rank falls into.


XMAD:ORY
29GF Score
Oryzon Genomics SA XMAD:ORY
Profitability Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Oryzon Genomics has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Oryzon Genomics's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-5.766 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Oryzon Genomics has an F-score of 4 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Oryzon Genomics Business Description

Other Exchanges ORYZF:USA0RDB:UKORN:Germany
Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
29GF Score

Get the complete analysis for XMAD:ORY

Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.85
Price